Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingAspirus Arise Aldurazyme Prior Auth Coverage | Ope…
    Ask Trek AI about this page
    CurrentAspirus ArisePOLICY: Enzyme Replacement Therapy -Aldurazyme Utilization Management Medical Policy

    Enzyme Replacement Therapy - Aldurazyme (laronidase) Utilization Management Medical Policy

    Customize your policy alerts

    Sign up for Aspirus Arise POLICY: Enzyme Replacement Therapy -Aldurazyme Utilization Management Medical Policy alerts

    Get alerted when POLICY: Enzyme Replacement Therapy -Aldurazyme Utilization Management Medical Policy changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization, coverage criteria, dosing, and prescribing specialist requirements for Aldurazyme (laronidase) for treatment of Mucopolysaccharidosis type I (MPS I) across Aspirus Medicare Plans and related Aspirus Arise lines.

    Policy Summary
    PayerAspirus Arise
    PolicyEnzyme Replacement Therapy - Aldurazyme (laronidase) Utilization Management Medical Policy
    Policy CodePolicy POLICY: Enzyme Replacement Therapy -Aldurazyme Utilization Management Medical Policy
    Change TypeNo material change
    Effective DateJan 1, 2021
    Last ReviewApr 15, 2026
    Next Review DateApr 15, 2026
    Key ActionObtain prior authorization and document diagnosis by enzyme assay or molecular genetic testing and that Aldurazyme is prescribed by or in consultation with an appropriate specialist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 yearstandard approval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    0.58 mg/kg
    per-dose maximum
    weeklyfrequency
    biallelic IDUAgenetic confirmation option

    Coverage Criteria for Aldurazyme (laronidase)

    FDA-Approved Indication (Initial and Renewal)

    Covered when ALL of the following are met:

    FDA-Approved Indication and Prescriber: 1) Mucopolysaccharidosis Type I (Hurler, Hurler-Scheie, Scheie). Approve for 1 year if BOTH A and B are met.
    A - Diagnostic confirmation: A) Diagnosis established by ONE of: i. laboratory test demonstrating deficient α-L-iduronidase activity in leukocytes, fibroblasts, plasma, or serum; OR ii. molecular genetic test demonstrating biallelic pathogenic or likely pathogenic IDUA gene variants.
    B - Prescriber requirement: B) Aldurazyme is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder sub-specialist, or a physician who specializes in treatment of lysosomal storage disorders.
    Dosing limits: Each dose must not exceed 0.58 mg/kg IV, no more frequently than once weekly.0.58 mg/kg weekly

    Requests for doses outside established dosing will be considered case-by-case by a clinician.

    Coverage is not recommended for circumstances that are not listed in the Recommended Authorization Criteria. Requests that fall outside the specified criteria may be denied; the criteria will be updated as new published data become available.

    Confirmation of MPS I diagnosis by molecular genetic testing when biallelic pathogenic or likely pathogenic IDUA variants are identified

    Molecular confirmation as alternative to enzyme assay: Molecular genetic testing demonstrating biallelic pathogenic or likely pathogenic IDUA variants is accepted as an alternative to an enzyme assay to establish the diagnosis of MPS I.

    Testing must demonstrate biallelic pathogenic or likely pathogenic variants in IDUA.

    Coding and Dosing Limits

    Drug referencemixed
    laronidase (Aldurazyme)HCPCS/brand biologic (documented as Aldurazyme - laronidase intravenous infusion - Genzyme) (no explicit HCPCS/NDC listed in document)
    Per-dose maximum
    Per-dose limit (mg/kg)Each dose must not exceed 0.58 mg/kg administered IV
    Maximum frequencyNo more frequently than once weekly
    Route of administrationIntravenous (IV) infusion
    Approval duration when criteria metApprove for 1 year if diagnostic and prescriber criteria are satisfied

    Provider Actions, Authorization, and Documentation Requirements

    Prior Authorization

    Prior authorization required for Aldurazyme (approve 1 year if criteria met)

    Prior authorization is recommended for medical benefit coverage of Aldurazyme; approve for 1 year when the patient meets the diagnostic and prescriber criteria. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside the established dosing will be considered case‑by‑case by a clinician.

    • Approval duration: 1 year when criteria A and B are met
    • Extended approvals permitted if criteria and dosing continue to be met
    • Dose exceptions reviewed case‑by‑case by Medical Director or Pharmacist
    Step Therapy

    Relation to alternative therapy (HSCT) — when to use Aldurazyme

    Hematopoietic stem cell transplantation (HSCT) is an indicated alternative for severe forms of MPS I in children <2 years who are cognitively intact; Aldurazyme is used when HSCT is not indicated (for children who already have cognitive decline) or is appropriate for older patients.

    Definitions and Diagnostic Criteria

    Definitive diagnosis of MPS I
    Diagnostic method — enzyme assayDemonstration of deficient α-L-iduronidase activity in leukocytes, fibroblasts, plasma, or serum
    Diagnostic method — molecular testingMolecular genetic test demonstrating biallelic pathogenic or likely pathogenic IDUA gene variants
    Accepted as alternativeMolecular genetic testing is accepted as an alternative to enzyme assay for diagnostic confirmation
    Disease contextMPS I (Hurler, Hurler-Scheie, Scheie) is caused by α-L-iduronidase deficiency leading to glycosaminoglycan accumulation

    Covered Indications

    Confirmation of MPS I diagnosis by molecular genetic testing when biallelic pathogenic or likely pathogenic IDUA variants are identified

    Molecular confirmation as alternative to enzyme assay: Molecular genetic testing demonstrating biallelic pathogenic or likely pathogenic IDUA variants is accepted as an alternative to an enzyme assay to establish the diagnosis of MPS I.

    Testing must demonstrate biallelic pathogenic or likely pathogenic variants in IDUA.

    Eligibility Requirements

    No top-level eligibility requirements are specified in this policy.

    Background on MPS I and Aldurazyme

    Mucopolysaccharidosis type I (MPS I) is an autosomal recessive lysosomal storage disease caused by deficiency of α-L-iduronidase, leading to accumulation of glycosaminoglycans and progressive multi-organ dysfunction. Clinical features include characteristic facies, corneal clouding, cardiomyopathy, hepatosplenomegaly, respiratory insufficiency, skeletal abnormalities, and cognitive impairment. Definitive diagnosis is by demonstrating deficient α-L-iduronidase activity in leukocytes, fibroblasts, plasma, or serum, or by identifying biallelic pathogenic or likely pathogenic variants in IDUA.

    Policy Summary
    PayerAspirus Arise
    PolicyEnzyme Replacement Therapy - Aldurazyme (laronidase) Utilization Management Medical Policy
    Policy CodePolicy POLICY: Enzyme Replacement Therapy -Aldurazyme Utilization Management Medical Policy
    Change TypeNo material change
    Effective DateJan 1, 2021
    Last ReviewApr 15, 2026
    Next Review DateApr 15, 2026
    Key ActionObtain prior authorization and document diagnosis by enzyme assay or molecular genetic testing and that Aldurazyme is prescribed by or in consultation with an appropriate specialist.
    SourceLink
    On This Page
    Coverage Criteria for Aldurazyme (laronidase)Coding and Dosing LimitsProvider Actions, Authorization, and Documentation RequirementsDefinitions and Diagnostic CriteriaCovered IndicationsEligibility RequirementsBackground on MPS I and Aldurazyme
    • HSCT indicated for severe MPS I in children <2 years who are cognitively intact
    • Aldurazyme does not cross the blood–brain barrier and may be used in children with prior cognitive decline or in older patients
    Documentation Required

    Required clinical documentation and dosing conformity

    Documentation must demonstrate the diagnosis of MPS I by either enzyme assay showing deficient α‑L‑iduronidase activity or by molecular genetic testing showing biallelic pathogenic/likely pathogenic IDUA variants, and must show Aldurazyme is prescribed by or in consultation with an appropriate specialist; dosing requested should conform to the policy's dosing limits.

    • Diagnostic evidence: enzyme assay in leukocytes, fibroblasts, plasma, or serum OR molecular genetic test demonstrating biallelic pathogenic/likely pathogenic IDUA variants
    • Prescriber: geneticist, endocrinologist, metabolic disorder sub‑specialist, or physician who specializes in lysosomal storage disorders
    • Dosing must not exceed 0.58 mg/kg IV no more frequently than once weekly
    Denial Risk

    Denial triggers — requests outside Recommended Authorization Criteria

    Coverage is not recommended for requests that fall outside the Recommended Authorization Criteria; such requests may be denied.

    • Requests outside the listed Recommended Authorization Criteria are not recommended for approval
    • Criteria will be updated as new published data are available
    Note

    Prescriber requirement — specialist must prescribe or consult

    Aldurazyme must be prescribed by or in consultation with a specialist experienced in MPS I (geneticist, endocrinologist, metabolic disorder sub‑specialist, or physician who specializes in lysosomal storage disorders).

    • Prescriber requirement is mandatory for approval
    • Specialist involvement may be via direct prescription or documented consultation